Shanghai Henlius Biotech, Inc. announces that based on the nomination of Mr. Jun Zhu, the Chief Executive Officer of the Company, Ms. Wei Huang has been appointed as the President of the Company with effect from 1 October 2023. Ms. Huang is mainly responsible for the production quality operation and engineering project construction management of the Company, and business decisions of the Company's subsidiary, Aton (Shanghai) Biotech Co. Ltd., and will report to Mr. Zhu, the CEO.

Mr. Zhu ceased to be the President with effect from the same date but will continue to act as the executive director, CEO and Chief Financial Officer of the Company. Ms. Huang, aged 55, joined the Group in December 2019 and served as the senior vice president of Shanghai Henlius Biopharmaceutical Co. Ltd., a subsidiary of the Company, and served as the senior vice president and chief operating officer of the Company since October 2020.

Prior to joining the Group, Ms. Huang has around 25 years of senior management and leadership experience in the pharmaceutical and biotechnology industries, including process development, technology transfer, manufacturing, engineering project construction management, etc.